Developing precise medicines for triple negative breast cancer

August 21, 2020

Toronto -- Taking advantage of a cancer cell's altered metabolism that drives its runaway growth, Princess Margaret researchers are zeroing in on these molecular changes to help them develop more precise drug targets for one of the most deadly breast cancers.

Triple negative breast cancer is a highly aggressive subtype of breast cancers, representing 15-20% of breast cancer cases, but accounting for 25% of breast cancer deaths. In addition, it has a higher metastatic rate within five years of diagnosis and poorer overall survival rate compared to receptor positive cancer subtypes.

Scientists don't know why, but this cancer is also more common among Black and younger women.

"This disease has no precision medicine," says Dr. Mathieu Lupien, Senior Scientist, Princess Margaret Cancer Centre, "so patients are treated with chemotherapy because we don't have a defined therapeutic target. Initially, it works for some patients, but close to a quarter of patients recur within five years from diagnosis, and many develop chemotherapy-resistant tumours.

"These savage statistics mean that we must improve our understanding of the molecular basis for this cancer's development to discover effective, precise targets for drugs, and a companion test to identify which patients are most likely to benefit the most from such a therapy."

In research led by Princess Margaret Senior Scientists Drs. Cheryl Arrowsmith and Mathieu Lupien published in Nature Communications, August 21, 2020, the scientific team found a promising approach with a protein biomarker that could potentially identify the best patients for more precise, targeted therapy in the future.

Using a collection of different patient-derived cell lines from triple negative breast cancer, researchers were able to test their sensitivity to 'chemical probes' (experimental, drug-like compounds) against inhibitors of a metabolic gatekeeper called GLUT1. They found a correlation or link between cells with varying levels of RB1, a protein involved in cell metabolism, as well as a long-established tumour suppressor protein, and decreased growth in these cancer cells.

Altered metabolism drives explosive cancer growth

All cancers have altered metabolic states, explains Dr. Arrowsmith, because their explosive growth requires huge amounts of energy, such as glucose, to nourish their survival and growth - despite being bombarded with chemotherapy in this specific cancer.

Having access to diverse cell models of triple-negative breast cancer allows us to distinguish where the potential drug will work, and where it won't, says Dr. Lupien, who is also an Associate Professor in the Department of Medical Biophysics. "Without this broad spectrum of samples, we might have missed the subset of triple-negative breast cancers that respond to our compound."

Specifically, the compound targets GLUT1, part of the pathway transporting glucose into a cell to increase metabolic energy in the subset of cancer cells with high levels of RB1 protein- in effect stopping them from growing.

Blocking this pathway "starved" the cancer cells, making them more responsive or sensitive to the chemical compound, demonstrating this as a promising target for new anticancer approaches.

This work shows that differing levels of RB1 can be used as a biological biomarker to discriminate between treatment responders and non-responders in the future, says Dr. Arrowsmith.

Major challenge in cancer research

Matching the right patient to the right drug is a major challenge in cancer research and treatment, says Dr. Arrowsmith, who is also Chief Scientist for the Structural Genomics Consortium Toronto laboratories and Professor of Medical Biophysics at the University of Toronto.

She points out that multiple changes in cancer cells drive their abnormal growth, including genetic, epigenetic, metabolic and chromosomal changes that mutate and change over time.

This heterogeneity in tumour cells, which is constantly changing and adapting over time, enables cancer cells to thrive and evade conventional therapies.

That's why many new potential drugs fail, says Dr. Arrowsmith, because these multiple combinations of changes in cancer cells are complex and dynamic.

"What we're trying to do is to understand in detail what subset of drugs are effective at targeting the minute molecular changes in the cancer cells.

"It's like whack-a-mole when you try and treat cancer with one drug. As soon as you figure out how to stop a mechanism that drives the cell rogue, the cancer cells adapt and keep on growing.

"That's the big challenge in treating cancer. The more we understand about the molecular complexity of cancer cells, the more we can target with precision.

"And the more we can build up a pharmacy of cancer drugs matched to specific changes in the cancer cell, the greater the chance of a cure."
-end-
Support for the research was provided by: Terry Fox Research Institute, Canadian Cancer Research Society, Ontario Institute for Cancer Research, Canadian Institute for Health Research, Princess Margaret Cancer Foundation, Gattuso-Slaight Personalized Cancer Medicine Fund at Princess Margaret, and the Structural Genomics Consortium.

University Health Network

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.